Friday, July 10, 2026

pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)

Chiesi Farmaceutici S.p.A

Chiesi Farmaceutici S.p.A clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT HQ
6,080 Employees
EMA registrant Type
Company details
Status
Public
HQ
Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
Employees
6,080
Programs
20
Drugs
38
Patents
0
Intelligence · Clinical Programs

Chiesi Farmaceutici S.p.A projects

3 ClinicalTrials.gov programs sponsored by Chiesi Farmaceutici S.p.A.

Chiesi Farmaceutici S.p.A has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 0.9% sodium chloride aqueous solution for IV infusion

    Chiesi Farmaceutici S.p.A

    Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial
  2. CHF6001 DPI

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 2 small molecule active

    1 trial
  3. CLI-05993AA9-01

    Chiesi Farmaceutici S.p.A

    Mild to moderate asthma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Chiesi Farmaceutici S.p.A have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.